August 25th 2025
Answering all the questions ophthalmologists may have ahead of the EURETINA Congress in Paris, France
August 19th 2025
The province's public health insurance scheme, Régie de l’assurance maladie du Québec (RAMQ), covers faricimab for three indications
August 15th 2025
Salvation of ocular tissues and visual acuity are dependent on early diagnosis, investigators emphasised
August 14th 2025
Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond
August 13th 2025
New financing will support the company's lead retinitis pigmentosa programme, among other projects
Moorfields Eye Hospital INSIGHT research hub will collaborate with artificial intelligence development company Insitro
The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases
Phase 3 COAST trial fails to meet primary endpoints for wet AMD, Opthea reports
The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration
Study examines real-world treat-and-extend outcomes and background factors of macular atrophy
The study demonstrated that the number of injections needed gradually decreased during the follow-up period
Researchers raise awareness of macular pathologies which mimic AMD and GA
Inherited retinal diseases have disease processes distinct from age-related macular degeneration and geographic atrophy, but may present with "phenocopy" clinical signs
EDI-OCT and CVI findings can shed light on choroidal vascular physiology following COVID-19 pneumonia
Investigators measured the choroidal structures using enhanced depth imaging optical coherence tomography
First patient dosed in Phase 1/2 ASTRA study for Stargardt disease therapy SB-007 (SpliceBio)
SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial
Advanced therapies in neovascular AMD and DMO: Experts weigh in
A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden
Renal dysfunction negatively impacts effect of diabetic macular oedema therapy
Additionally, the prognosis of macular oedema may help clinicians evaluate renal function, investigators reported
Experts say revakinagene taroretcel-lwey approval may represent dawn of new treatments for neurodegenerative conditions
Clinicians react to the US approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) for macular telangiectasia type 2
NASA astronaut and clinical lead will deliver keynote at International SPECTRALIS Symposium
In a keynote speech, Warren Hoburg and Tyson J. Brunstetter, OD, PhD, will discuss in-orbit imaging and spaceflight-associated neuro-ocular syndrome
US FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2
The encapsulated cell therapy from Neurotech Pharmaceuticals is the first FDA-approved treatment for MacTel
EMA provides positive ATMP opinion for gene therapy products OCU410 and OCU410ST
The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease
Cognition Therapeutics announces publication reviewing potential of zervimesine (CT1812) in dry AMD
One in vitro study included in the manuscript was conducted in collaboration with researchers at the University of Southhampton in the United Kingdom
Study: Cigarette smoking negatively affects choroidal vascularity
The investigators' findings suggest that CVI is a valuable noninvasive predictive biomarker for monitoring vascular changes in patients who smoke
Association between the triglyceride-glucose index and central retinal artery occlusion
The researchers reported a “notable” correlation which could serve as a predictive biomarker
Prevent Blindness highlights free resources during Retinopathy of Prematurity Awareness Week
The initiative marks the second annual ROP Awareness week, running from 24 February to 2 March, 2025
Study demonstrates visual acuity improvements following gene therapy for AIPL1-associated inherited retinal dystrophies
Researchers indicated that paediatric patients with Leber congenital amaurosis experienced improvements in vision
UK MHRA issues approval for Formycon aflibercept biosimilar FYB203 (Ahzantive)
The biosimilar to aflibercept (Eylea) has already received approval in the EU and US
Why education must extend beyond patients to make a difference in diabetic eye disease
Francesco Bandello, MD, FEBO, discusses the Diabetic Eye Conditions Coalition and a five-point call to action
Postoperative considerations for retinal detachments following keratoprosthesis implantation
Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery
Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks
The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March
Angiogenesis 2025: The global forecast for AI-driven home OCT
Professor Anat Loewenstein, MD, speaks about her presentation from the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting
Retinal biomarkers in OCT imaging may have predictive applications for nAMD
The authors evaluated shallow irregular pigment epithelial detachment, subretinal hyperreflective material, subretinal fluid, intraretinal fluid and other baseline OCT biomarkers
Healthy lifestyles translate to lower risk of retinal disease
Researchers screened for outcomes such as the presence of retinal diseases including age-related macular degeneration and retinal vein occlusion
Italian study illuminates positive outcomes and common complications of SING IMT implantation
The implant was tested in eyes of patients with bilateral age-related macular degeneration who underwent cataract surgery
COVID-19 may impact anatomy of retina and functional vision
Choroidal and retinal changes were examined with optical coherence tomography angiography
US FDA approves continuous delivery ranibizumab treatment (Susvimo, Genentech) for diabetic macular oedema
Previously, Susvimo was called the Port Delivery System with ranibizumab in the United States
Ocugen, Inc. receives European Medicines Agency ATMP designation for new gene therapy OCU400
OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication
European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars
Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration
Viralgen and Axovia Therapeutics enter partnership, target retinal dystrophy in Bardet-Biedl Syndrome
The lead gene therapy candidate, AXV-101, is expected to enter clinical development in mid-2025